Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

The problem with COPD is you have obstruction ... improve patients' breathing and decreases the exacerbations. And there are a host of medications we can use now that barely existed or didn ...

Asthma–chronic obstructive pulmonary disease (COPD ... trials to evaluate specific drug interventions on important outcomes such as lung function, acute exacerbations, quality of life and ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

The drug provides both bronchodilation ... could also be heading for approval in COPD – at the second attempt – after reducing exacerbations in the phase 3 MATINEE trial, while Amgen and ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...